Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
3. May 2024 • News
3. May 2024 • News
Point-of-care-testing (POCT) is a critical part of healthcare, with the potential to improve patient outcomes and expand access to services. At the 2024 POCT Meeting in Leipzig, international experts discussed how these vital technologies are evolving.
At the invitation of the Fraunhofer IZI and ‚WIR! sind DIANA‘, more than 130 experts from around the world gathered in Leipzig to learn and network. A roster of keynote speakers from renowned institutions such as McMaster University and Ludwig-Maximilians-Universität Munich shared their insights with participants.
Topics covered included the future of clinical and home care testing, the rapid pandemic response and the global importance of POCT testing for HIV and malaria. From DNA nanotechnology to high-precision POC device manufacturing, new ways in which POCT can revolutionize the diagnostics landscape were also highlighted.
Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.
A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.
The European Commission has approved the Saxon ERDF/JTF program for the funding period 2021 to 2027.